TQB3616 + anlotinib

A combination therapy consisting of **TQB3616** and **anlotinib**. TQB3616 is under investigation as an anti-cancer agent, most likely a small molecule targeting androgen receptor pathways (as inferred from naming conventions and context), but direct characterization in the results above is not detailed. **Anlotinib** is an oral small molecule receptor tyrosine kinase inhibitor. Anlotinib simultaneously targets VEGFR1-3 (vascular endothelial growth factor receptor), FGFR1-4 (fibroblast growth factor receptor), PDGFR-α/β (platelet-derived growth factor receptor), c-kit (stem cell factor receptor), and possibly other kinases. It exerts anti-angiogenic and anti-proliferative effects, inhibiting tumor blood vessel growth and tumor cell proliferation[1][5][7]. The combination is under development, likely for cancer indications, but specific published clinical data on "TQB3616 + anlotinib" as a pairing are currently unavailable in the above references.